

# GENetic and clinical Predictors Of treatment response in Depression

<b>Submission date</b> 17/09/2003	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 19/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 27/09/2011	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Glyn Lewis

**Contact details**  
Division of Psychiatry  
Cotham House  
Cotham Hill  
Bristol  
United Kingdom  
BS6 6JL  
+44 0117 954 6796  
Glyn.lewis@bristol.ac.uk

## Additional identifiers

**Protocol serial number**  
G0200243

## Study information

**Scientific Title**

**Acronym**

GENPOD

**Study objectives**

We wish to identify genetic and clinical predictors of response to SSRIs and NaRIs in depressive illness. Hypotheses:

1. Those who are homozygous for the insertion allele polymorphism in the promoter region of the 5HT transporter who are allocated SSRIs will have an improved response compared to those on NaRIs. This also implies that those who are not homozygous will have reduced response on SSRIs compared to those on NaRIs.
2. Those who have more severe depressive disorders who are allocated NaRIs and less severe disorder allocated SSRIs will have a better response compared to the other two groups

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Mental and Behavioural Disorders

**Interventions**

1. Reboxetine 4mg bd
2. Paroxetine 20mg

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Reboxetine, Paroxetine

**Primary outcome(s)**

Beck depression inventory total score (BDI) at 6 weeks adjusted for baseline BDI score.

**Key secondary outcome(s))**

Not provided at time of registration

**Completion date**

22/05/2008

## Eligibility

**Key inclusion criteria**

18-74 years with the more severe depressions in whom the GP and patient have already agreed that antidepressants should be prescribed. We will therefore only include those with a Clinical Interview Schedule - Revised (CIS-R) score of  $\geq 20$ , a Beck Depression Inventory (BDI) score of  $\geq 15$  and a diagnosis of International Statistical Classification of Diseases and Related Health Problems, tenth revision (ICD-10) depressive episode F32 and F33 (from CIS-R).

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

74 years

**Sex**

Not Specified

**Key exclusion criteria**

Pregnant and breast feeding women, patients with psychotic illness, alcohol or substance abuse problems, patients with medical contraindications to Citalopram or Reboxetine. (June 2006: Exclusion criteria were provided as follows: Potential subjects who have taken antidepressant medication within 2 weeks, who cannot complete self-administered scales, who have a psychosis or major substance or alcohol abuse. The GP will exclude anyone who has medical contraindications or in whom participation in the trial is not appropriate.)

**Date of first enrolment**

23/02/2004

**Date of final enrolment**

22/05/2008

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**  
**Division of Psychiatry**  
Bristol  
United Kingdom  
BS6 6JL

## **Sponsor information**

**Organisation**  
Medical Research Council (UK)

## **Funder(s)**

**Funder type**  
Research council

**Funder Name**  
Medical Research Council (MRC) (G0200243) (UK)

**Alternative Name(s)**  
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2011		Yes	No
<a href="#">Protocol article</a>	protocol	22/05/2008		Yes	No